WASHINGTON A House committee on Friday said it will investigate New York-based ImClone Systems Inc.’s conduct in the development of its well-publicized drug for colorectal cancer.
Inspire Pharmaceuticals Inc. said it’s not likely that the first Phase III trial of its lead product for dry eye will reach its endpoints. The negative news sent Inspire’s stock tumbling 73 percent.
Inspire Pharmaceuticals Inc. said it’s not likely that the first Phase III trial of its lead product for dry eye will reach its endpoints. The negative news sent Inspire’s stock tumbling 73 percent.
An accumulation of products in preclinical development has forced Burlingame, Calif.-based Valentis Inc. to scale back its work force by about 42 percent.
An accumulation of products in preclinical development has forced Burlingame, Calif.-based Valentis Inc. to scale back its work force by about 42 percent.
